A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Clinical trial NCT05747729 · RECRUITING

Trial details

NCT number: NCT05747729
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Carcinoma

Start date: 2023-06-21
Primary completion: 2026-10-28
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.